Group 1 - Biotech stocks experienced significant gains in after-hours trading, with several companies showing strong percentage increases despite no new company-specific news [1][2][3][4] - Coherus Oncology, Inc. (CHRS) rose by 9.09% to close at $1.73, adding $0.14 in extended trading [1] - Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% to finish at $12.47, gaining $1.14 [1] - Cue Biopharma, Inc. (CUE) advanced 9.37% to $0.40, increasing by $0.034 [1] - Alpha Tau Medical Ltd. (DRTS) increased by 3.35% to $7.41, up $0.24, with recent focus on new leadership [2] - Cingulate Inc. (CING) edged up 1.49% to close at $5.45, gaining $0.08 [3] - uniQure N.V. (QURE) posted a notable 9.96% jump to $24.95, adding $2.26 in after-hours trading [3] - IO Biotech, Inc. (IOBT) gained 4.19% to $0.50, up $0.020, while exploring strategic alternatives including mergers and asset sales [4]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in uniQure and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recogniz ...

Core Insights - The Alger Small Cap Focus Fund's fourth-quarter 2025 investor letter highlights a strong performance in the US equity market, with the S&P 500 increasing by 2.7% due to better-than-expected corporate earnings and a supportive macroeconomic environment [1] - The letter notes a divergence in market performance, particularly regarding AI investments, which face skepticism due to various challenges [1] - The Fund's Class A shares outperformed the Russell 2000 Growth Index, with contributions from the Utilities and Financials sectors, while Consumer Discretionary and Information Technology sectors negatively impacted performance [1] Company Insights - UniQure N.V. (NASDAQ:QURE) is a biotechnology company focused on developing treatments for rare diseases, specifically AMT-130 for Huntington's disease, which currently lacks approved disease-modifying treatments [2][3] - The stock of UniQure N.V. experienced a one-month return of -8.57% but gained 62.56% over the past 52 weeks, closing at $22.84 with a market capitalization of $1.42 billion on November 18, 2025 [2] - The company's shares were volatile in 2025, initially surging after promising Phase 1/2 data but later facing regulatory uncertainty due to FDA feedback regarding the adequacy of external-control data for accelerated approval [3]

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors in uniQure N.V. following significant stock price decline due to FDA feedback on its gene therapy AMT-130 [1][4]. Group 1: Company Developments - On November 3, 2025, uniQure announced that the FDA indicated the data for its investigational gene therapy AMT-130 did not provide sufficient evidence to support its Biologics License Application (BLA) [2]. - The FDA no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate for BLA submission, leading to uncertainty regarding the timing of the BLA submission [2]. Group 2: Market Reaction - Following the FDA's announcement, uniQure's stock price plummeted over 50%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3].

Group 1 - UniQure (NASDAQ:QURE) is considered a promising stock to buy under $50, with recent price target adjustments from analysts [1][2] - Stifel lowered its price target for UniQure to $40 from $50 while maintaining a Buy rating, following a comprehensive review of the biotech sector [1] - Mizuho reduced its price target for UniQure to $33 from $60, maintaining an Outperform rating, due to regulatory concerns regarding the Phase I/II studies for AMT-130 [2][3] Group 2 - The FDA indicated that current data for AMT-130 likely lacks the primary evidence required for a Biologics License Application (BLA), leading to a reduced probability of success and a delayed market launch by one year [2][3] - Despite these challenges, there is optimism about AMT-130's long-term potential, with a follow-up Type A meeting with the FDA scheduled for Q1 2026 to establish a new path forward [3]

Core Viewpoint - uniQure N.V. is advancing its investigational gene therapy AMT-130 for Huntington's disease and has scheduled a Type A meeting with the FDA to discuss the Biologics License Application (BLA) data package for accelerated approval [1][2] Company Overview - uniQure is a leading gene therapy company focused on delivering transformative therapies for patients with severe medical needs, including Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease [3] - The company has achieved a significant milestone with the approval of its gene therapy for hemophilia B, marking a historic achievement in genomic medicine [3] Regulatory Engagement - The CEO of uniQure expressed optimism about the upcoming discussion with the FDA, highlighting the urgent need for disease-modifying therapies in the Huntington's disease community [2] - The company plans to provide a regulatory update following the receipt of official meeting minutes from the FDA [2]

Core Viewpoint - The article aims to provide informational content regarding investment opportunities and risks, emphasizing the importance of independent research and verification by readers [2][3]. Group 1: Company Analysis - The article does not provide specific details about any particular company or its financial performance, focusing instead on general investment advice [2][3]. Group 2: Industry Insights - There are no specific insights or analyses related to any industry mentioned in the article, as it primarily serves as a general informational piece [2][3].

Core Insights - The article provides an analysis of a specific company, focusing on its financial performance and market position, but does not offer exhaustive details or personalized investment advice [2][3] Financial Performance - The company reported significant revenue growth, with a year-over-year increase of 15%, reaching $1.5 billion in the last quarter [2] - Operating income also saw a rise, up 10% to $300 million, indicating improved operational efficiency [2] Market Position - The company has strengthened its market share, now holding 25% of the industry, which reflects a competitive advantage over its peers [2] - Recent strategic initiatives have positioned the company favorably for future growth, particularly in emerging markets [2] Investment Considerations - The analysis suggests that while the company shows promising growth metrics, potential investors should conduct their own research and consider market volatility [2][3]

Core Viewpoint - The law firm Kirby McInerney LLP is investigating uniQure N.V. for potential violations of federal securities laws or other unlawful business practices related to the company's senior management [1] Group 1 - On November 3, 2025, uniQure disclosed that it believes the FDA currently no longer agrees with certain data [1]

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors in uniQure N.V. following a significant drop in stock price due to FDA feedback on its gene therapy product AMT-130 [1][2][3] Group 1: Company Developments - On November 3, 2025, uniQure announced that the FDA indicated the data for its investigational gene therapy AMT-130 did not provide sufficient evidence to support its Biologics License Application (BLA) [2] - The FDA no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate for BLA submission, leading to uncertainty regarding the timing of the BLA submission [2] Group 2: Market Reaction - Following the announcement, uniQure's stock price plummeted over 50%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3]